NewEdge Advisors’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.49M | Sell |
14,734
-504
| -3% | -$86.2K | 0.01% | 989 |
|
|
2025
Q4 | $2.57M | Buy |
15,238
+1,008
| +7% | +$164K | 0.01% | 948 |
|
|
2025
Q3 | $2.05M | Sell |
14,230
-254
| -2% | -$34.7K | 0.01% | 1000 |
|
|
2025
Q2 | $1.83M | Sell |
14,484
-500
| -3% | -$61.4K | 0.01% | 978 |
|
|
2025
Q1 | $1.92M | Buy |
14,984
+1,195
| +9% | +$162K | 0.01% | 885 |
|
|
2024
Q4 | $1.82M | Buy |
13,789
+1,893
| +16% | +$266K | 0.01% | 866 |
|
|
2024
Q3 | $1.73M | Buy |
11,896
+263
| +2% | +$38.1K | 0.01% | 851 |
|
|
2024
Q2 | $1.6M | Buy |
11,633
+1,944
| +20% | +$260K | 0.01% | 853 |
|
|
2024
Q1 | $1.33M | Sell |
9,689
-24
| -0.2% | -$3.28K | 0.01% | 856 |
|
|
2023
Q4 | $1.32M | Sell |
9,713
-2,229
| -19% | -$272K | 0.01% | 822 |
|
|
2023
Q3 | $1.46M | Sell |
11,942
-718
| -6% | -$91.3K | 0.02% | 707 |
|
|
2023
Q2 | $1.61M | Sell |
12,660
-4,277
| -25% | -$556K | 0.02% | 670 |
|
|
2023
Q1 | $2.19M | Sell |
16,937
-4,679
| -22% | -$612K | 0.03% | 504 |
|
|
2022
Q4 | $1.83M | Buy |
21,616
+5,747
| +36% | +$743K | 0.05% | 345 |
|
|
2022
Q3 | $1.86M | Sell |
15,869
-16,634
| -51% | -$2.07M | 0.03% | 450 |
|
|
2022
Q2 | $3.82M | Buy |
32,503
+18,726
| +136% | +$2.22M | 0.06% | 288 |
|
|
2022
Q1 | $1.8M | Buy |
13,777
+1,445
| +12% | +$188K | 0.03% | 455 |
|
|
2021
Q4 | $1.88M | Buy |
12,332
+5
| +0% | +$774 | 0.03% | 474 |
|
|
2021
Q3 | $1.99M | Buy |
12,327
+6,659
| +117% | +$1.12M | 0.05% | 320 |
|
|
2021
Q2 | $928K | Sell |
5,668
-10
| -0.2% | -$1.54K | 0.02% | 515 |
|
|
2021
Q1 | $855K | Sell |
5,678
-231
| -4% | -$36.7K | 0.03% | 499 |
|
|
2020
Q4 | $895K | Buy |
5,909
+174
| +3% | +$24.9K | 0.03% | 438 |
|
|
2020
Q3 | $777K | Buy |
5,735
+578
| +11% | +$78.4K | 0.03% | 449 |
|
|
2020
Q2 | $705K | Buy |
5,157
+1,994
| +63% | +$254K | 0.03% | 456 |
|
|
2020
Q1 | $341K | Sell |
3,163
-1,394
| -31% | -$160K | 0.02% | 563 |
|
|
2019
Q4 | $549K | Sell |
4,557
-283
| -6% | -$31.6K | 0.02% | 495 |
|
|
2019
Q3 | $486K | Buy |
4,840
+1,861
| +62% | +$195K | 0.02% | 495 |
|
|
2019
Q2 | $325K | Sell |
2,979
-564
| -16% | -$60K | 0.02% | 503 |
|
|
2019
Q1 | $396K | Sell |
3,543
-353
| -9% | -$38.7K | 0.03% | 452 |
|
|
2018
Q4 | $376 | Buy |
3,896
+1,505
| +63% | +$160K | 0.02% | 433 |
|
|
2018
Q3 | $292K | Sell |
2,391
-57
| -2% | -$6.71K | 0.02% | 500 |
|
|
2018
Q2 | $271 | Buy |
2,448
+242
| +11% | +$25.9K | 0.02% | 435 |
|
|
2018
Q1 | $226K | Buy |
+2,206
| New | +$245K | 0.03% | 434 |
|
|
2017
Q3 | – | Sell |
-150
| Closed | -$15.5K | – | 703 |
|
|
2017
Q2 | $15.5K | Buy |
+150
| New | +$14.8K | ﹤0.01% | 814 |
|
Other funds holding IBB
CB
NewEdge Advisors's IBB Position: Q1 2026 in Review
NewEdge Advisors reduced its iShares Biotechnology ETF (IBB) stake by 3.3% in Q1 2026, selling an estimated $86.2K and leaving 14,734 shares worth $2.49M. The position accounts for 0.01% of the portfolio, ranked #989.
NewEdge Advisors first reported a position in IBB in Q2 2017 and has held it in 34 quarters since. The position peaked at $3.82M in Q2 2022. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- NewEdge Advisors held 14,734 shares of iShares Biotechnology ETF worth $2.49M as of Q1 2026.
- NewEdge Advisors sold 504 iShares Biotechnology ETF shares in Q1 2026, an estimated $86.2K.
- iShares Biotechnology ETF made up 0.01% of NewEdge Advisors's portfolio in Q1 2026, its #989 holding.
- NewEdge Advisors first reported a position in iShares Biotechnology ETF in Q2 2017 and has held it in 34 quarters since.
- NewEdge Advisors's iShares Biotechnology ETF position peaked at $3.82M in Q2 2022.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.